LONG-TERM EFFICACY OF FLUOCINOLONE IN EYES WITH IRIS-LENS DIAPHRAGM DISRUPTION AND PCME WITH MEDICATION FIXED IN THE SCLERA (MEFISTO).

Autor:	Herold TR; Department of Ophthalmology, University Hospital, LMU Munich, Germany., Vounotrypidis E; Department of Ophthalmology, University Hospital, Ulm, Germany., Liegl R; Department of Ophthalmology, University Hospital, Bonn, Germany; and., Koenig SF; Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom., Priglinger SG; Department of Ophthalmology, University Hospital, LMU Munich, Germany., Wolf A; Department of Ophthalmology, University Hospital, Ulm, Germany.
Jazyk:	angličtina
Zdroj:	Retina (Philadelphia, Pa.) [Retina] 2022 Jul 01; Vol. 42 (7), pp. 1392-1398. Date of Electronic Publication: 2022 Mar 15.
DOI:	10.1097/IAE.0000000000003472
Abstrakt:	Purpose: The aim of our prospective off-label, interventional clinical trial was to evaluate the efficacy and safety of the fluocinolone-loop-anchoring technique over two years in eyes with iris-lens diaphragm disruption and pseudophakic cystoid macular edema. Methods: In 10 eyes, scleral fixation of fluocinolone implant was performed. Main outcome measures were the development of best-corrected visual acuity (BCVA), central retinal thickness over 24 months, and general safety of the procedure. Results: A significant improvement to 0.57 ± 0.38 log MAR (Snellen 20/80) (range 0-1.30) was observed (P = 0.003) at 1 month. Further improvement to 0.45 ± 036 log MAR (Snellen 20/60) was observed until month 18 (P = 0.081). Mean central retinal thickness decreased by 22% from 601.6 ± 235.5 µm to 449.1 ± 128.9 µm at 1 month. In one patient, the implant has to be removed at Month 7 because of elevated intraocular pressure and one patient after globe rupture had a retinal redetachment at Month 4. Conclusion: In this study, we showed that the treatment of recalcitrant pseudophakic cystoid macular edema with scleral fixated fluocinolone implant in eyes with disruption of the iris-lens diaphragm provides good anatomical and functional results with a reasonable safety profile over 24 months in eyes where pseudophakic cystoid macular edema is otherwise difficult to treat and often left untreated. (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu